Vaxcyte (PCVX) Change in Accured Expenses (2019 - 2026)

Vaxcyte (PCVX) has reported Change in Accured Expenses for 8 consecutive years, with -$15.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 4.16% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at $1.7 million (down 44.51% YoY), while the FY2025 annual figure was $2.3 million, down 75.81% from the prior year.
• Change in Accured Expenses fell to -$15.0 million in Q1 2026 per PCVX's latest filing, from $6.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $13.0 million in Q2 2025 and bottomed at -$15.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $814588.2 across 5 years, with a median of $2.5 million in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 1613.2% in 2024 and fell as far as 362.28% in 2024.
• Vaxcyte's Change in Accured Expenses stood at $7.2 million in 2022, then sank by 42.43% to $4.1 million in 2023, then surged by 101.96% to $8.3 million in 2024, then declined by 25.37% to $6.2 million in 2025, then sank by 341.21% to -$15.0 million in 2026.
• Business Quant data shows PCVX's Change in Accured Expenses at -$15.0 million in Q1 2026, $6.2 million in Q4 2025, and -$2.5 million in Q3 2025.